Concise Syntheses of Vinylcitrate, Isocitrate and Citrafungin A, a Potent Inhibitor of Fungal Geranylgeranyltranferase I
Concise Syntheses of Vinylcitrate, Isocitrate and Citrafungin A, a Potent Inhibitor of Fungal Geranylgeranyltranferase I
批准号:
EP/E033792/1
负责人:
Tony Barrett
金额:
$12.62万
依托单位:
依托单位国家:
英国
项目类别:
Research Grant
财政年份:
2007
资助国家:
英国
项目状态:
已结题
起止时间:
2007 至 --
中文摘要
合成有机化学是一门对生物医学研究和药物创新至关重要的学科。它直接影响到新药发现和开发过程的所有阶段。新的HIT活性化合物的发现及其生产药物先导结构的优化依赖于药物设计、迭代合成和生物学评价。2006年可能不太明显的是,天然产物分离、全合成和半合成对于发现未来商业上成功的药物至关重要。医学界对真菌病有相当大的警觉。白念珠菌、新生隐球菌、卡氏肺孢子虫和烟曲霉等病原体是免疫功能低下患者相当大的发病率和死亡率的原因。这些患者包括艾滋病患者,移植手术的接受者,他们需要接受终身免疫抑制药物的治疗,以防止组织排斥反应,以及接受癌症化疗的患者,他们的免疫系统因抗癌药物的副作用而受损。目前治疗严重系统性真菌感染的方法是不足的,因为现在唑类抗真菌药物存在耐药性问题,而更有效的杀菌剂多烯类药物是有毒的。因此,迫切需要针对严重真菌疾病的新疗法,以及对大量局部真菌感染的管理。其次,结核病是世界范围内一种传染病导致的主要死亡原因,并且已经达到了世界卫生组织(WHO)宣布全球进入紧急状态的地步。世卫组织预测,如果新的抗结核病药物不能迅速开发,到2020年将有10亿新感染者。大约90%的感染者最初逃脱了疾病的症状。在这些免疫系统健康的人中,杆菌进入一种非复制(NRP)状态,这种状态可以持续数十年,没有明显的疾病迹象,但仍保持着感染的潜力。目前结核病(TB)的一线药物治疗虽然对活动性疾病有效,但对NRP状态无效。这必然导致全世界发病率和死亡率大幅上升,而这场灾难对撒哈拉以南非洲来说尤其不祥。资助申请者正在寻求资金,以支持一名博士生的培训和研究,该博士生将进行一种有效的抗真菌药物--柠檬香精A的全合成。这种具有生物活性的天然产物是一种关键的真菌酶-香叶基香叶基转移酶I的抑制剂,该酶对真菌细胞壁的生物合成至关重要。因此,柠檬香精A是一种极好的热门化学结构,它是设计治疗人类真菌感染的新抗真菌药物的基础。此外,这些研究与发现治疗潜伏期疾病的新的抗结核药物有关。柠檬香精A的类似物可以很好地对抗异柠檬酸裂解酶(ICL),ICL是处于NRP状态的结核分枝杆菌的关键酶。这些研究应该导致合成一系列天然产物的类似物用于生物测定,并鉴定出更好的化合物以供进一步开发。
英文摘要
Synthetic organic chemistry is a discipline of paramount importance to biomedical research and pharmaceutical innovation. It impacts directly on all stages of the discovery and development process for new medicines. The discovery of new hit active compounds and their optimisation to produce pharmaceutical lead structures depend on drug design, iterative synthesis and biological evaluation. What may be less apparent in 2006 is the vital importance of natural product isolation, total synthesis and semi-synthesis for the discovery of the commercially successful drugs of the future. There is considerable alarm amongst the medical profession regarding fungal disease. Pathogens such as Candida albicans, Cryptococcus neoformans, Pneumocystis carinii and Aspergillus fumigatus are the cause of considerable morbidity and mortality in immuno-compromised patients. These include patients with fully blown AIDS, recipients of transplant surgery, who need to be treated for life with immuno-suppressants to prevent tissue rejection, and patients undergoing cancer chemotherapy, whose immune system is impaired by the side effects of their anti-cancer drugs. Current therapies for the treatment of serious systemic fungal infection are deficient since there now are resistance problems with azole fungistatic agents and the more potent fungicidal polyene drugs are toxic. As such, there is urgent need for novel therapies for serious fungal disease and for the management of the legions of topical fungal infections. Secondly, TB is the principal cause of death due to an infectious disease worldwide and has reached such proportions that the World Health Organisation (WHO) has declared a global emergency. WHO predicts 1 billion newly infected people by the year 2020 if new anti-TB drugs are not rapidly developed. Approximately 90% of individuals who are infected initially escape symptoms of the disease. In these individuals with healthy immune systems, the bacilli enter a non-replicating (NRP) state that can persist for decades without overt signs of disease, yet maintaining an infectious potential. Current first-line drug treatments for tuberculosis (TB), while effective toward active disease, are impotent towards the NRP state. This has the inevitable consequence of significantly elevated levels of morbidity and mortality worldwide with the catastrophe being especially ominous for sub-Saharan Africa. The grant applicant is seeking funding to support the training and research of one PhD student who will carry out the total synthesis of citrafungin A, a potent antifungal agent. This bioactive natural product acts as an inhibitor of a key fungal enzyme, geranylgeranyltransferase I. This enzyme is crucial for the biosynthesis of the fungal cell wall. As such, citrafungin A is an excellent hit chemical structure on which to base the design of new antifungal agents for the treatment of fungal infections in man. In addition, these studies are relevant to the discovery of new anti-tuberculosis agents for the treatment of the disease in its latent state. Analogues of citrafungin A may well show activity against isocitrate lyase (ICL), which is a critical enzyme for Mycobacterium tuberculosis in the NRP state. The studies should lead to this synthesis of a range of analogues of the natural products for bioassay and the identification of superior compounds for further development.
期刊论文(5)
专著(0)
科研奖励(0)
会议论文
Correction to "A Simple, Short, and Flexible Synthesis of Viridiofungin Derivatives".
对“Viridiofungin 衍生物的简单、简短且灵活的合成”的更正。
DOI:
10.1021/acs.joc.9b01172
发表时间:
2019
期刊:
The Journal of organic chemistry
影响因子:
--
作者:
[Goldup SM]
通讯作者:
Goldup SM
Concise Syntheses of the Meroterpenoids: Facilitating the Discovery of New Classes of Pharmaceuticals
-
批准号:EP/N022815/1
-
项目类别:Research Grant
-
资助金额:$56.66万
-
财政年份:2016
-
负责人:Tony Barrett
-
依托单位:
Group 2: Elements of 21st Century Catalysis
-
批准号:EP/I014853/1
-
项目类别:Research Grant
-
资助金额:$42.87万
-
财政年份:2011
-
负责人:Tony Barrett
-
依托单位:
The Development of Inhibitors of Cdk Activating Kinase (CAK)
-
批准号:EP/F008856/1
-
项目类别:Research Grant
-
资助金额:$12.31万
-
财政年份:2007
-
负责人:Tony Barrett
-
依托单位:
Two Directional Benzyne Ring Annulation in the Total Synthesis of Sch 47554
-
批准号:EP/E047432/1
-
项目类别:Research Grant
-
资助金额:$35.62万
-
财政年份:2007
-
负责人:Tony Barrett
-
依托单位:
Peripherally-Functionalised Porphyrazines and seco-Porphyrazines: Synthesis and Applications of Novel Metallomacrocycles
-
批准号:EP/E009026/1
-
项目类别:Research Grant
-
资助金额:$45.17万
-
财政年份:2006
-
负责人:Tony Barrett
-
依托单位:
海外基金